Evaluation of the Chinese Medicinal Herb, Graptopetalum paraguayense, as a Therapeutic Treatment for Liver Damage in Rat Models

Table 3

Therapeutic effects of Graptopetalum paraguayense (GP) on DMN-induced liver fibrosis in rats via biochemical analysis (2).

Numeric variable	p ^a			Categorical variable^b
	Drug^c	Week^d	Drug × Week	1st to 2nd wk	3rd to 4th wk	5th to 6th wk
Albumin	0.1285	0.3895	0.2342	−0.17	0.38	0.83
GPT	0.0003	0.6769	0.7826	−225	−360	−501
GOT	<0.0001	0.3298	0.2164	−390	−816	−1355
Bilirubin	<0.0001	0.6728	0.7539	−0.48	−0.75	−1
AKP	<0.0001	0.6172	0.1147	−303	−230	−107
LDH	<0.0001	0.0132	0.0013	−63	−141	−363
Globulin	0.1341	0.029	0.0254	−0.75	0.58	1.65
Triglyceride	0.0658	0.4116	0.355	−78	−84	−5
AFP	0.0031	0.8992	0.6289	−0.2	−0.1	−0.1
CHOL	0.324	0.9847	0.3248	−16.5	−3.6	4.2
BUN	0.0444	0.5896	0.4293	−13.8	−13.6	−1.6
ACP	0.097	0.0004	0.0006	1.8	−0.7	−3.6
PT	0.0285	0.7278	0.9627	−2.4	−2.5	−5.3
PLT	0.0008	0.3879	0.4526	129	249	476

^a: Significant correction is marked in bold at the 0.05 level by two-way ANOVA.
^b: Average_{DMN + GP}-Average_DMN in 1st to 2nd, 3rd to 4th or 5th to 6th week.
^c: DMN or DMN + GP treatment groups.
^d: 1st to 2nd, 3rd to 4th or 5th to 6th week.